Peptides in the news
Peptides in the News
Regulatory, policy, and professional news links organized by date. Sources are limited to FDA, USP, AP, and other high-credibility references.
FDA advisory committee
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting materials
Official FDA agenda and briefing documents for BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon 503A review.
FDA panel news
FDA panel narrowly backs unapproved peptide drugs
Independent news coverage of the PCAC vote and safety-data debate around BPC-157, TB-500, KPV, and related peptides.
Compounding policy
Human Drug Compounding Policies and Rules
FDA policy index noting current compounding guidance, Federal Register notices, and GLP-1 bulk-substance activity.
GLP-1 enforcement
FDA intends to take action against non-FDA-approved GLP-1 drugs
FDA statement on unapproved compounded GLP-1 products, marketing claims, and quality/safety concerns.
GLP-1 safety
FDA concerns with unapproved GLP-1 drugs used for weight loss
FDA page summarizing concerns about compounded semaglutide/tirzepatide, salt forms, counterfeit products, and adverse-event reports.
503A guidance
Interim policy on compounding using bulk drug substances under section 503A
Final guidance for state-licensed pharmacies and physicians using bulk drug substances while FDA develops the 503A list.
503B guidance
Interim policy on compounding using bulk drug substances under section 503B
Final guidance for outsourcing facilities while FDA evaluates nominated bulk substances for the 503B list.
Sterile compounding
USP <797> Pharmaceutical Compounding – Sterile Preparations
Official USP chapter preview covering minimum standards for compounded sterile preparations.
Medication safety
Dosing errors associated with compounded injectable semaglutide
FDA alert for providers, compounders, and patients about dose-conversion and multi-dose vial risks.
Peptide safety status
Bulk substances that may present significant safety risks
FDA Category 2 page identifying nominated bulk substances with potential significant safety risks, including certain peptides.
503B list
503B bulk drug substances list
FDA list of bulk drug substances with and without identified clinical need for outsourcing-facility compounding.
Bulk substances
Bulk drug substances used in compounding
FDA overview of supplier controls and statutory limits for 503A and 503B bulk-drug compounding.
503B requirements
Bulk drug substances used in compounding under section 503B
FDA page describing the clinical-need and shortage-list pathways, COA expectations, and supplier registration requirements.
Supplier quality
FDA to compounders: know your bulks and excipients suppliers
FDA quality-control reminder for API and excipient sourcing, testing, and documentation.
Links open the original source. This library is for professional reference review only and is not medical advice, treatment advice, dosing guidance, or product-use instruction.